Nasdaq
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel. Also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotide artery in carotids endarterectomy surgery.
Roles derived from SEC Form 4 filings.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $129.4M | $154.4M | $161.7M | $193.5M | $219.9M | $249.6M |
| Gross profit | $84.6M | $101.4M | $104.9M | $127.0M | $150.9M | $178.5M |
| Operating income | $28.8M | $36.4M | $26.8M | $36.7M | $52.3M | $67.9M |
| Net income | $21.2M | $26.9M | $20.6M | $30.1M | $44.0M | $57.7M |
| Diluted EPS | $1.04 | $1.25 | $0.93 | $1.34 | $1.93 | $2.52 |
| Operating cash flow | $34.8M | $35.1M | $25.4M | $36.8M | $44.1M | $81.3M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | 65.4% | 65.7% | 64.9% | 65.7% | 68.6% | 71.5% |
| Operating margin | 22.3% | 23.6% | 16.6% | 19.0% | 23.8% | 27.2% |
| Net margin | 16.4% | 17.4% | 12.7% | 15.6% | 20.0% | 23.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $55.8M | $54.8M | $55.7M | $59.9M | $64.2M | $61.0M | $64.5M | $66.6M |
| Gross profit | $38.5M | $37.2M | $38.6M | $41.4M | $45.0M | $46.0M | $46.2M | $48.4M |
| Operating income | $14.4M | $13.1M | $12.9M | $12.6M | $16.1M | $20.3M | $18.8M | $17.8M |
| Net income | $11.8M | $11.1M | $11.1M | $11.0M | $13.8M | $17.4M | $15.5M | $15.7M |
| Diluted EPS | $0.52 | $0.49 | $0.48 | $0.48 | $0.60 | $0.75 | $0.69 | $0.68 |
| Operating cash flow | $9.6M | $14.2M | $15.2M | $9.0M | $20.3M | $28.8M | $23.2M | $15.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 68.9% | 67.8% | 69.3% | 69.2% | 70.0% | 75.3% | 71.7% | 72.7% |
| Operating margin | 25.7% | 24.0% | 23.1% | 21.1% | 25.1% | 33.3% | 29.2% | 26.7% |
| Net margin | 21.2% | 20.3% | 20.0% | 18.4% | 21.5% | 28.4% | 24.1% | 23.6% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-04 | LeMaitre George W· Chairman and CEO | Award | 11,974 | $0.00 | $0.00 | filing |
| 2026-06-04 | LeMaitre George W· Chairman and CEO | Gift | 11,974 | $0.00 | $0.00 | filing |
| 2026-05-08 | LeMaitre George W· Chairman and CEO | Sale | 27,881 | $108.69 | $3.0M | filing |
| 2026-05-08 | Kamke Trent G· Senior V. P., Operations | Sale | 2,928 | $107.00 | $313,286.92 | filing |
| 2026-05-07 | LeMaitre George W· Chairman and CEO | Sale | 18,600 | $107.64 | $2.0M | filing |
| 2026-05-07 | Ross Bridget A | Sale | 5,044 | $111.10 | $560,366.21 | filing |
| 2026-05-07 | Jasinski Lawrence J | Sale | 3,943 | $110.00 | $433,730.00 | filing |
| 2026-05-07 | Ross Bridget A | Option exercise | 3,444 | $48.60 | $167,378.40 | filing |
| 2026-05-07 | Jasinski Lawrence J | Option exercise | 865 | $101.12 | $87,468.80 | filing |
| 2026-05-07 | Ross Bridget A | Option exercise | 1,600 | $47.19 | $75,504.00 | filing |
| 2026-05-07 | Jasinski Lawrence J | Option exercise | 924 | $54.65 | $50,496.60 | filing |
| 2026-05-07 | Jasinski Lawrence J | Option exercise | 1,069 | $47.19 | $50,446.11 | filing |
| 2026-04-22 | Pellegrino Joseph P JR | Option exercise | 2,941 | $35.48 | $104,346.68 | filing |
| 2026-03-11 | Roberts David B· President and Director | Sale | 3,312 | $107.68 | $356,585.81 | filing |
| 2026-03-11 | Kamke Trent G· Senior V. P., Operations | Sale | 2,625 | $108.50 | $284,812.50 | filing |
| 2026-03-11 | Kamke Trent G· Senior V. P., Operations | Option exercise | 2,625 | $35.48 | $93,135.00 | filing |
| 2026-03-10 | LeBlanc Dorian Paul· Chief Financial Officer | Tax withholding | 96 | $109.20 | $10,483.20 | filing |
| 2026-03-10 | LeBlanc Dorian Paul· Chief Financial Officer | Option exercise | 2 | $0.00 | $0.00 | filing |
| 2026-03-02 | LeMaitre George W· Chairman and CEO | Sale | 55,930 | $107.81 | $6.0M | filing |
| 2026-03-02 | LeMaitre George W· Chairman and CEO | Gift | 5,000 | $0.00 | $0.00 | filing |
| 2026-02-27 | Roberts David B· President and Director | Sale | 8,464 | $106.80 | $903,957.74 | filing |
| 2026-02-27 | Kamke Trent G· Senior V. P., Operations | Sale | 1,044 | $110.29 | $115,142.76 | filing |
| 2026-02-26 | LeMaitre George W· Chairman and CEO | Sale | 150,000 | $106.76 | $16.0M | filing |
| 2026-02-26 | LeMaitre George W· Chairman and CEO | Tax withholding | 496 | $113.69 | $56,390.24 | filing |
| 2026-02-26 | Roberts David B· President and Director | Tax withholding | 134 | $113.69 | $15,234.46 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.